Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0C2QU
|
|||
| Drug Name |
PMID26560530-Compound-25
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
National Cancer Center (S. Korea)
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C10H8OS3
|
|||
| Canonical SMILES |
COC1=CC=C(C=C1)C2=CC(=S)SS2
|
|||
| InChI |
1S/C10H8OS3/c1-11-8-4-2-7(3-5-8)9-6-10(12)14-13-9/h2-6H,1H3
|
|||
| InChIKey |
KYLIZBIRMBGUOP-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 532-11-6
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:31221
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Blautia obeum
Show/Hide Hierarchy
|
[1] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Blautia obeum was decreased by Anethole trithione (adjusted p-values: 2.26E-06). | |||
|
Studied Microbe: Coprococcus comes
Show/Hide Hierarchy
|
[1] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Coprococcus comes was decreased by Anethole trithione (adjusted p-values: 3.43E-03). | |||
|
Studied Microbe: Dorea formicigenerans
Show/Hide Hierarchy
|
[1] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Dorea formicigenerans was decreased by Anethole trithione (adjusted p-values: 1.39E-05). | |||
|
Studied Microbe: Roseburia intestinalis
Show/Hide Hierarchy
|
[1] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Roseburia intestinalis was decreased by Anethole trithione (adjusted p-values: 9.82E-04). | |||
|
Studied Microbe: Ruminococcus bromii
Show/Hide Hierarchy
|
[1] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Ruminococcus bromii was decreased by Anethole trithione (adjusted p-values: 2.26E-05). | |||
|
Studied Microbe: Ruminococcus torques
Show/Hide Hierarchy
|
[1] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Ruminococcus torques was decreased by Anethole trithione (adjusted p-values: 1.20E-05). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tissue transglutaminase (TG2) | Target Info | Inhibitor | [2] |
| Target's Patent Info | Tissue transglutaminase (TG2) | Target's Patent Info | [2] | |
| KEGG Pathway | Huntington's disease | |||
| Pathway Interaction Database | Beta1 integrin cell surface interactions | |||
| Thromboxane A2 receptor signaling | ||||
| Alpha9 beta1 integrin signaling events | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 2 | Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.